Abstract | BACKGROUND: Older women with early-stage breast cancer experience higher rates of non- breast cancer-related death. We examined factors associated with cause-specific death in a large cohort of breast cancer patients treated with extended adjuvant endocrine therapy. METHODS: In the MA.17 trial, conducted by the National Cancer Institute of Canada Clinical Trials Group, 5170 breast cancer patients (median age = 62 years; range = 32-94 years) who were disease free after approximately 5 years of adjuvant tamoxifen treatment were randomly assigned to treatment with letrozole (2583 women) or placebo (2587 women). The median follow-up was 3.9 years (range 0-7 years). We investigated the association of 11 baseline factors with the competing risks of death from breast cancer, other malignancies, and other causes. All statistical tests were two-sided likelihood ratio criterion tests. RESULTS: During follow-up, 256 deaths were reported (102 from breast cancer, 50 from other malignancies, 100 from other causes, and four from an unknown cause). Non- breast cancer deaths accounted for 60% of the 252 known deaths (72% for those > or = 70 years and 48% for those < 70 years). Two baseline factors were differentially associated with type of death: cardiovascular disease was associated with a statistically significant increased risk of death from other causes (P.002), and osteoporosis was associated with a statistically significant increased risk of death from other malignancies (P.05). An increased risk of breast cancer-specific death was associated with lymph node involvement (P < .001). Increased risk of death from all three causes was associated with older age (P < .001). CONCLUSIONS:
|
Authors | Judith-Anne W Chapman, Daniel Meng, Lois Shepherd, Wendy Parulekar, James N Ingle, Hyman B Muss, Michael Palmer, Changhong Yu, Paul E Goss |
Journal | Journal of the National Cancer Institute
(J Natl Cancer Inst)
Vol. 100
Issue 4
Pg. 252-60
(Feb 20 2008)
ISSN: 1460-2105 [Electronic] United States |
PMID | 18270335
(Publication Type: Journal Article, Randomized Controlled Trial, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Antineoplastic Agents, Hormonal
- Nitriles
- Receptors, Estrogen
- Receptors, Progesterone
- Triazoles
- Letrozole
|
Topics |
- Age Factors
- Aged
- Antineoplastic Agents, Hormonal
(therapeutic use)
- Breast Neoplasms
(chemistry, drug therapy, mortality)
- Canada
(epidemiology)
- Cardiovascular Diseases
(mortality)
- Cause of Death
- Chemotherapy, Adjuvant
- Disease-Free Survival
- Double-Blind Method
- Female
- Follow-Up Studies
- Humans
- Letrozole
- Middle Aged
- Neoplasms, Hormone-Dependent
(drug therapy, mortality)
- Nitriles
(therapeutic use)
- Osteoporosis, Postmenopausal
(mortality)
- Prospective Studies
- Receptors, Estrogen
(analysis)
- Receptors, Progesterone
(analysis)
- Research Design
- Risk Factors
- Triazoles
(therapeutic use)
|